Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||21 Apr 2021||Lorem|
|LoA Update: Ionis Pharmaceuticals' donidalorsen sodium for HAE sees an 8-point spike in FDA regulatory potential following positive Phase II||07 Apr 2021||William Newton|
|Ionis’ prekallikrein target for Phase IIa IONIS-PKK-LRx stands on par with approved prophylactic drugs in HAE; early data draws expert enthusiasm on activity||16 Mar 2021||William Newton|
|Akcea/Ionis’ AKCEA-APOCIII-LRx has bright efficacy prospects in Phase II hypertriglyceridemia trial but value in impacting CVD risk still debatable, experts say||25 Sep 2019||Reynald Castaneda|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer